Genome Therapeutics Posts Reduced Q3 Revenue, Strong R&D Growth, Widened Net Loss

genomeweb
360dx

Genome Therapeutics Posts Reduced Q3 Revenue, Strong R&D Growth, Widened Net Loss

Nov 12, 2002

This update serves to correct an error in fact. Third-quarter revenue derived from Genome Therapeutics' GenomeVision division fell by $1.3 million year over year, not $4.2 million as originally reported. GenomeWeb regrets the error.

To read the full story....

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

People in the News: Patrick Kaltenbach, Margo Georgiadis, William Bonello, More
In Brief This Week: SeraCare; Human Longevity; CareDx; Interpace Diagnostics; and More
Single-Cell Transcriptomics Studies Draw Cell Type Maps for Complete Animal
Biotheranostics Settles False Claims Allegations With DOJ for $2M
Genetic Signatures Gets CE Mark for 'Superbugs' Kit
New Products Posted to GenomeWeb: Thermo Fisher Scientific, Bio-Techne, Mission Bio, More

The Scan

Years and Years

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Diving Evolution

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

This Week in Science

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

Issues to Overcome

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

Main menu